tiprankstipranks
Lexaria’s Oral Drug Shows Promising Results Against Eli Lilly’s Injection
Company Announcements

Lexaria’s Oral Drug Shows Promising Results Against Eli Lilly’s Injection

Story Highlights
  • Lexaria’s oral formulation reduced adverse events by 47% compared to injections.
  • The oral drug maintained comparable efficacy in blood glucose reduction and insulin secretion.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.

Stay Ahead of the Market:

Lexaria Bioscience ( (LEXX) ) has provided an announcement.

Lexaria Bioscience Corp. announced partial final results from a human study comparing their oral DehydraTECH-tirzepatide to Eli Lilly’s injected Zepbound®. The study revealed that the oral formulation reduced adverse events by 47% and gastrointestinal-related adverse events by 54% compared to the injected version, while maintaining comparable efficacy in blood glucose reduction and insulin secretion. These results suggest that Lexaria’s oral drug delivery system may offer a more tolerable alternative for diabetes treatment, potentially strengthening its market position in the pharmaceutical industry.

More about Lexaria Bioscience

Lexaria Bioscience Corp. is a global innovator in drug delivery platforms, focusing on enhancing the effectiveness and tolerability of various pharmaceuticals.

YTD Price Performance: -10.43%

Average Trading Volume: 154,929

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $37.7M

For a thorough assessment of LEXX stock, go to TipRanks’ Stock Analysis page.

Related Articles
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App

Latest News Feed

More Articles